" class="no-js "lang="en-US"> Eden Pharma - Medtech Alert
Friday, May 02, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Eden Pharma | PTF

Eden Pharma

About Eden Pharma

Eden Pharma

Eden Pharma is a developer and retailer of bespoke strains of marijuana for medical and recreational use. They are the 12th largest cannabis company according to Global Cannabis Times and the biggest in the UK and Europe. Eden Pharma is focused on research into cannabis to build a diverse portfolio of assets, including innovative medicinal and recreational applications.

Related Story

Appointments

 Eden Pharma Announces the Appointment of Mike Parker to Board of Directors | Eden Health

Eden Pharma Announces the Appointment of Mike Parker to Board of Directors

November 24 2022

Eden Pharma, the company disrupting the CBD health and wellness industry, announces the appointment of Mike […]